Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy

Experimental and Therapeutic Medicine

Volumn 6, Issue 3, 2013, Pages 649-656

  Ma, Ruixia ^a   Liu, Liqiu ^a   Liu, Xuemei ^a   Wang, Yan ^a   Jiang, Wei ^a   Xu, Luo ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Albuminuria; Podocyte injury; Triptolide

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; INSULIN; NEPHRIN; OSTEOPONTIN; PODOCIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TRIPTOLIDE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL DAMAGE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULUS BASEMENT MEMBRANE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NONHUMAN; PODOCYTE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

EID: 84880500041     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1226     Document Type: Article

References (34)

1. Murphy M, Crean J, Brazil DP, Sadlier D, Martin F and Godson C: Regulation and consequences of differential gene expression in diabetic kidney disease. Biochem Soc Trans 36: 941-945, 2008.
2. Stitt-Cavanagh E, MacLeod L and Kennedy C: The podocyte in diabetic kidney disease. Scientific World Journal 14: 1127-1139, 2009.
3. Wolf G, Chen S and Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634,2005.
4. Mitu GM, Wang S and Hirschberg R: BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 293: F1641-F1648, 2007.
5. Patrakka J and Tryggvason K: Nephrin-a unique structural and signaling protein of the kidney filter. Trends Mol Med 13: 396-403, 2007.
6. Marshall SM: The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des 13: 2713-2720, 2007.
7. Wolf G and Ziyadeh FN: Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106: 26-31, 2007.
8. Kikuchi Y, Imakiire T, YamadaM, et al: Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 20: 1573-1581, 2005.
9. Williams MD and Nadler JL: Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7: 242-248, 2007.
10. Ziyadeh FN and Wolf G: Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4: 39-45, 2008.
11. Wei X, Gong J, Zhu J, et al: Therapeutic effects of trip-tolide on interleukin-10 gene-deficient mice with colitis. Int Immunopharmacol 8: 1808-1812, 2008.
12. Chan SC, Shum DK, Tipoe GL, Mak JC, Leung ET and Ip MS: Upregulation of ICAM-1 expression in bronchial epithelial cells by airway secretions in bronchiectasis. Respir Med 102: 287-298, 2008.
13. Lin N, Liu C, Xiao C, et al: Triptolide, a diterpenoid triepoxide, suppresses infammation and cartilage destruction in collagen-induced arthritis mice. Biochem Pharmacol 73: 136-146, 2007.
14. Song HX, Gong J and Chen W: Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 25: 416-418, 2005 (In Chinese).
15. Ma RX, Liu LQ, Xu Y and Jiang W: Protective effect of triptolide on renal tissues in type 2 diabetic rats. Chinese Journal of Hypertension 16: 1120-1124, 2008 (In Chinese).
16. Yamamoto Y, Maeshima Y, Kitayama H, et al: Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53: 1831-1840, 2004
17. Danda RS, Habiba NM, Rincon-Choles H, et al: Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 68: 2562-2571, 2005
18. Guo XH, Liu ZH, Li H, et al: A novel rat model of type 2 diabetes mellitus. Chinese Journal of Nephrology Dialysis & Transplantation 9: 351-355, 2000 (In Chinese).
19. Jefferson JA, Shankland SJ and Pichler RH: Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74 22-36, 2008.
20. Hauser PV, Collino F, Bussolati B and Camussi G: Nephrin and endothelial injury. Curr Opin Nephrol Hypertens 18: 3-8, 2009
21. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van der Woude FJ, et al: Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 71: 637-645, 2007
22. Mathieson PW: Update on the podocyte. Curr Opin Nephrol Hypertens 18: 206-211, 2009
23. Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K and Hugo C: Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 87 1290-1299, 2009
24. Eto N, Wada T, Inagi R, et al: Podocyte protection by darbe-poetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 72: 455-463, 2007
25. Zhang Y, Chen B, Hou XH, et al: Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J (Engl) 120: 988-995, 2007
26. Chen ZH, Qin WS, Zeng CH, et al: Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 77: 974-988, 2010.
27. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS and Liu ZH: Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 74 596-612, 2008.
28. Gao Q, Shen W, Qin W, et al: Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant 25: 3539-3547, 2010.
29. Tarabra E, Giunti S, Barutta F, et al: Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 58: 2109-2118, 2009
30. Lee EY, Chung CH, Khoury CC, et al: The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF-beta, increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 297: F85-F94, 2009
31. Tossidou I, Starker G, Kruger J, et al: PKC-alpha modulates TGF-beta signaling and impairs podocyte survival. Cell Physiol Biochem 24 627-634, 2009
32. Takano Y, Yamauchi K, Hayakawa K, et al: Transcriptional suppression of nephrin in podocytes by macrophages: roles of infammatory cytokines and involvement of the PI3KAkt pathway. FEBS Lett 581: 421-426, 2007
33. Kim YH, Lee SH, Lee, Choi SW, Park JW and Kwon TK: Triptolide inhibits murine inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase. Eur J Pharmacol 494: 1-9, 2004
34. Zhou Y, Ling EA and Dheen ST: Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 102: 667-678, 2007